Printer Friendly

FUJISAWA USA, INC. WILL CONTINUE TO DEFEND ITS ADENOSCAN AGREEMENT WITH MEDCO RESEARCH, INC.

 DEERFIELD, Ill., July 26 /PRNewswire/ -- In response to the July 23 announcement by Medco Research, Inc. (AMEX: MRE) of its intention to partner with Abbott Laboratories (NYSE: ABT) in the manufacture of Adenoscan, Fujisawa USA, Inc. (FUSA) today announced that it will continue to defend its original 1988 development and license agreement with Medco for the drug, which is used for the detection of heart disease.
 "We maintain our belief that FUSA has in no way breached the terms of the 1988 Agreement," said Gary Schmidt, vice president, general counsel and secretary of FUSA.
 FUSA today notified Medco by letter of its position that its proposed agreement with Abbott Laboratories violated FUSA's rights under the 1988 Agreement. The letter further stated that FUSA "will hold Medco fully liable for any and all damages ensuing" from Medco's actions and reserved the right to seek injunctive relief where appropriate.
 Schmidt emphasized that FUSA will continue to defend the exclusive manufacturing and marketing rights granted it in the original contract.
 Fujisawa USA, Inc., headquartered in Deerfield, Ill., is a manufacturer of proprietary and multi-source pharmaceutical products and a subsidiary of Fujisawa Pharmaceutical Co., Ltd. based in Osaka, Japan.
 -0- 7/26/93
 /CONTACT: Paula Waters of Fujisawa USA, Inc., 312-329-7532/
 (MRE ABT)


CO: Fujisawa USA, Inc.; Medco Research, Inc. ST: Illinois IN: MCT SU:

TM -- NY112 -- 5974 07/26/93 20:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 26, 1993
Words:230
Previous Article:FLETCHER CHALLENGE CANADA LIMITED ANNOUNCES EARNINGS
Next Article:HAND DRYERS VERSUS THE PAPER INDUSTRY
Topics:


Related Articles
FUJISAWA USA FILES IND APPLICATION FOR VESTAR'S AMBISOME(R)
MEDCO RESEARCH FILES COMPLAINT AGAINST FUJISAWA PHARMACEUTICAL CO.
MEDCO RESEARCH'S ADENOCARD APPROVED IN CANADA
MEDCO RESEARCH SIGNS AGREEMENT TO DEVELOP AND MARKET ADENOSINE IN JAPAN
FUJISAWA RECEIVES FDA CLEARANCE FOR NEW TRANSPLANT DRUG
FUJISAWA USA PREPARES FOR ADENOSCAN(R) APPROVAL, PURSUES COMPLAINT AGAINST MEDCO RESEARCH AND ABBOTT
FUJISAWA QUALIFIES TO MANUFACTURE ADENOSCAN
MEDCO RESEARCH RECEIVES FDA 'APPROVABLE LETTER' ON ADENOSCAN
FUJISAWA USA TO MANUFACTURE KEY PRODUCT AT NEW CEPHALOSPORIN PLANT
FUJISAWA USA, INC. RECEIVES APPROVAL FOR PROGRAF (IMMUNOSUPPRESSIVE AGENT) IN CANADA

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters